Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTATE-2
NCT03504566Phase 4Withdrawn
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Nov 2017
- Primary completion
- Jun 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of linagliptin, empagliflozin, telmisartan and sulodexide in diabetic nephropathy (DN), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Strongest albuminuria-lowering effect at 48 weeks. Planned start Nov 2017; status: withdrawn.
02
Drugs
linagliptinempagliflozintelmisartansulodexide
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03504566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504566.